Halozyme Reports Second Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Halozyme Therapeutics (HALO) Tops Q2 EPS by 4c, Revenues Miss; Maintains FY19 Revenue Guidance Above Consensus
August 6, 2019 6:03 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $39.15 million versus the consensus estimate of $42.76 million.
Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year PeriodENHANZE® Partner Janssen Submits... More